SeSaM-Biotech enters antibody gene library market

SeSaM can be used as an innovative diversity generation method for any protein including antibodies and other therapeutic proteins.

In order to break into the antibody engineering market, SeSaM-Biotech started an antibody gene library campaign with a special offer for the first 50 customers.

Since Orthoclone – OKT3 was approved in 1986 as the first monoclonal treatment to fight kidney transplant rejection, the power of nature started to be harvested for medicine. Antibody therapy has emerged for cancer treatment, Crohn’s disease, rheumatoid arthritis etc. Unfortunately, nature did not evolve proteins to make the perfect drugs.

The ideal antibody based therapeutic has enhanced affinity, stability, specificity, expression level while having reduced antigenicity and optimized Fc. SeSaM technology can offer all this and more due to the fact that it opens the way to unavailable protein variants, up to now.

download >>